Cargando…

Pneumococcal Vaccination Provides Substantial Value for Money for Canadians

BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCV) to the Canadian childhood routine immunization schedules (RIS) resulted in significant benefits. The 7-valent PCV was added to all provinces’ RIS between 2002 and 2006. The 10-valent PCV was used in Ontario and Quebec for 12 to 18 mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peloquin, Francois, Breton, Marie-Claude, Wasserman, Matt, Wilson, Michele, McDade, Cheryl, Farkouh, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630886/ http://dx.doi.org/10.1093/ofid/ofx163.1186

Ejemplares similares

1428. Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination
por: Breton, Marie-Claude, et al.
Publicado: (2018)

Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
por: Wilson, Michele, et al.
Publicado: (2018)

Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis
por: Wilson, Michele R., et al.
Publicado: (2020)

Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”
por: Wilson, Michele R., et al.
Publicado: (2018)

Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
por: Wasserman, Matt D., et al.
Publicado: (2018)

Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
por: Wasserman, Matt, et al.
Publicado: (2019)

Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium
por: Wilson, Michele R., et al.
Publicado: (2021)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
por: Wasserman, Matthew, et al.
Publicado: (2018)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
por: Wilson, Michele, et al.
Publicado: (2023)

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
por: Perdrizet, Johnna, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease
por: Huang, Liping, et al.
Publicado: (2023)

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age
por: Wasserman, Matt D., et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’
por: Rozenbaum, Mark H., et al.
Publicado: (2022)

Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
por: Pugh, Sarah J., et al.
Publicado: (2018)

Remdesivir for COVID-19 in Europe: will it provide value for money?
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
por: Wasserman, Matt, et al.
Publicado: (2021)

Value for Money
Publicado: (1920)

How can robot-assisted surgery provide value for money?
por: Patel, Sejal, et al.
Publicado: (2021)

1384. Conceptual Economic Model Methodology for Infant Pneumococcal Conjugate Vaccine Program and its Impact on Antimicrobial Resistance
por: Farkouh, Raymond, et al.
Publicado: (2020)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

Best value for money
por: CERN Bulletin
Publicado: (2011)

The Money-Value Again
Publicado: (1892)

Addressing the potential threat of bioterrorism--value added to an improved public health infrastructure.
por: McDade, J E
Publicado: (1999)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK
por: Wasserman, M., et al.
Publicado: (2018)

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis
por: Pugh, Sarah, et al.
Publicado: (2020)

Money Value of Medical Attendance
Publicado: (1892)

Best Value for Money in Triptans
por: Curtiss, Frederic R.
Publicado: (2005)

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
por: Shen, Kunling, et al.
Publicado: (2018)

Was attending the conference worth value for money?
por: Bhattacharya, Surajit
Publicado: (2014)

Audit Reviewed: Value for Money in Medicine
por: Hoff, W. Van't
Publicado: (1983)

Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions
por: Shea, Kimberly M., et al.
Publicado: (2014)

Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
por: Farkouh, Raymond A., et al.
Publicado: (2015)

Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines
por: Haasis, Manuel Alexander, et al.
Publicado: (2015)

Does in vitro fertilization (IVF) treatment provide good value for money? A cost-benefit analysis
por: Keller, Elena, et al.
Publicado: (2023)

Time is money: the business value of web performance
por: Everts, Tammy
Publicado: (2016)

Assessing value-for-money in maternal and newborn health
por: Banke-Thomas, Aduragbemi, et al.
Publicado: (2017)

Hospital Accounts and Finance: Getting Value for Money
por: Stone, Joseph E.
Publicado: (1923)

Cannot write session to /tmp/vufind_sessions/sess_f0olmqhivm7aidthmjq77mc7q6